BMS enters two immuno-oncology deals

The drugmaker has paired up with Incyte and CytomyX in two separate deals.

Vieira, Everyday Health team up

Vieira, Everyday Health team up


The two-year collaboration leverages health content from Meredith Vieira's Lives project.

GSK stops Phase-II lupus trial

The drugmaker said JAK inhibitor GSK2586184 showed no effect in Phase II and has put an ulcerative colitis test on hold.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild


The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Merck, Ablynx ink immunotherapy deal

The two will explore cancer-attacking nanobodies.

Boehringer, Zealand reframe diabetes pact

The companies are changing the key compound.

AstraZeneca, J&J enter cancer collaborations

AstraZeneca, J&J enter cancer collaborations


The new deals seek out new strategies to address an expansive category.

OncoMed pairs up with Celgene for $177.25M

OncoMed pairs up with Celgene for $177.25M


The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.

Flavor of the week: antibiotics

AstraZeneca and Roche strike antibiotic deals.

Astellas inks neurodegenerative collaboration deal

Monday's announcement builds on a stream of recent R&D relationships.

Business briefs: Healthcare reform, Amgen, Pakistan pharma stance, digital marketing

Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows

Business briefs: AbbVie, FDA, and health spending projections

AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011

Business briefs: Merck, AbbVie, Roche, plus new FDA device rule

Complete Response letter slows Merck's suggamedex; AbbVie looks for next Humira; Roche drug gets breakthrough label; FDA effort to better track medical devices

Business briefs: Gilead, Boehringer, Rx sample ban

Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples

Business briefs: Boehringer Ingelheim, Sanofi, GSK, Teva

BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn's drug; and Teva joins cancer collaboration

Business briefs: GSK, Roche, Biogen Idec, Forest

FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO

Business briefs: Bristol-Myers Squibb, Zafgen, GSK, Shire

Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration

Business briefs: Sanofi, Celgene, plus changing cancer definitions

Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm

Business briefs: Amgen and Wockhardt

Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.

Business briefs: Astellas, ADA, AJMC, AARP

Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don't protect diabetics' hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.

Merck throws more staff behind Januvia; overall sales slid for quarter


Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise.

Email Newsletters